Steroids in chronic subdural hematomas (SUCRE trial): study protocol for a randomized controlled trial

Pierre-Louis Henaux, Pierre-Jean Le Reste, Bruno Laviolle, Xavier Morandi, Pierre-Louis Henaux, Pierre-Jean Le Reste, Bruno Laviolle, Xavier Morandi

Abstract

Background: Chronic subdural hematoma (CSDH) is a common neurological pathology, especially in older patients. The actual "gold standard" of treatment is surgical evacuation, with various techniques used across neurosurgical teams. Over the years, there has been growing evidence that inflammatory processes play a major role in the pathogenesis of CSDH. In that context, the use of corticosteroids has been proposed alone or as an adjuvant treatment to surgery. However, this practice remains very empirical and there is a need for high-quality-of-evidence studies to clarify the role of corticosteroids in the management of CSDH.

Methods/design: We propose a double-blind, randomized controlled trial comparing methylprednisolone versus placebo in the treatment of CSDH without clinical and/or radiological signs of severity. The treatment will be administered daily for a duration of 3 weeks, at a dose of 1 mg/kg. The primary endpoint will be the delay of occurrence of surgical treatment at 1 month following the introduction of the treatment. Secondary endpoints will include the rate of recourse to surgery, survival rate, quality of life and functional assessments, occurrence of systemic secondary effects and radiological assessment of the response to treatment. This multimodal assessment will be done at 1, 3 and 6 months. Two hundred and two patients (101 per arm) are expected to be included considering our primary hypotheses.

Discussion: This trial started in June 2016; its results may open interesting alternatives to surgery in the management of patients harboring a CSDH, and may provide insights into the natural history of this common pathology.

Trial registration: ClinicalTrials.gov, ID: NCT02650609 . Registered on 4 January 2016. Graphical output of the OBF boundaries.

Keywords: Chronic subdural hematoma; Conservative treatment; Corticosteroids; Elderly patients; Methylprednisolone.

Figures

Fig. 1
Fig. 1
Study flow chart. *Plasma sodium, potassium, and fasting glycemia/**fasting plasma cortisol

References

    1. Santarius T, Kirkpatrick PJ, Kolias AG, Hutchinson PJ. Working toward rational and evidence-based treatment of chronic subdural hematoma. Clin Neurosurg. 2010;57:112–22.
    1. Markwalder TM. Chronic subdural hematomas: a review. J Neurosurg. 1981;54:637–45. doi: 10.3171/jns.1981.54.5.0637.
    1. Bourgeois P, Sleiman M, Louis E, Haddad E, Touzet G, Fichten A, Lejeune JP. Chronic subdural hematoma in patients over 80 years of age. Neurochirurgie. 1999;45:124–8.
    1. Cousseau DH, Echevarría Martín G, Gaspari M, Gonorazky SE. Chronic and subacute subdural haematoma. An epidemiological study in a captive population. Rev Neurol. 2001;32:821–4.
    1. Kinsella K, Velkoff V. An aging world: 2001. Washington DC: US Government Printing Office; 2001.
    1. Almenawer SA, Farrokhyar F, Hong C, Alhazzani W, Manoranjan B, Yarascavitch B, Arjmand P, Baronia B, Reddy K, Murty N, Singh S. Chronic subdural hematoma management: a systematic review and meta-analysis of 34,829 patients. Ann Surg. 2014;259:449–57. doi: 10.1097/SLA.0000000000000255.
    1. Miranda LB, Braxton E, Hobbs J, Quigley MR. Chronic subdural hematoma in the elderly: not a benign disease. J Neurosurg. 2011;114:72–6. doi: 10.3171/2010.8.JNS10298.
    1. Feng J, Jiang J, Bao Y, Liang Y, Pan Y. Traumatic subdural effusion evolves into chronic subdural hematoma: two stages of the same inflammatory reaction? Med Hypotheses. 2008;70:1147–9. doi: 10.1016/j.mehy.2007.11.014.
    1. Frati A, Salvati M, Mainiero F, Ippoliti F, Rocchi G, Raco A, Caroli E, Cantore G, Delfini R. Inflammation markers and risk factors for recurrence in 35 patients with a posttraumatic chronic subdural hematoma: a prospective study. J Neurosurg. 2004;100:24–32. doi: 10.3171/jns.2004.100.1.0024.
    1. Heula AL, Ohlmeier S, Sajanti J, Majamaa K. Characterization of chronic subdural hematoma fluid proteome. Neurosurgery. 2013;73:317–33. doi: 10.1227/.
    1. Hong HJ, Kim YJ, Yi HJ, Ko Y, Oh SJ, Kim JM. Role of angiogenic growth factors and inflammatory cytokine on recurrence of chronic subdural hematoma. Surg Neurol. 2009;71:161–5. doi: 10.1016/j.surneu.2008.01.023.
    1. Kalamatianos T, Stavrinou LC, Koutsarnakis C, Psachoulia C, Sakas DE, Stranjalis G. PlGF and sVEGFR-1 in chronic subdural hematoma: implications for hematoma development. J Neurosurg. 2013;118:353–7. doi: 10.3171/2012.10.JNS12327.
    1. Kitazono M, Yokota H, Satoh H, Onda H, Matsumoto G, Fuse A, Teramoto A. Measurement of inflammatory cytokines and thrombomodulin in chronic subdural hematoma. Neurol Med Chir (Tokyo) 2012;52:810–5. doi: 10.2176/nmc.52.810.
    1. Pripp AH, Stanišić M. The correlation between pro- and anti-inflammatory cytokines in chronic subdural hematoma patients assessed with factor analysis. PLoS ONE. 2014;9 doi: 10.1371/journal.pone.0090149.
    1. Quan W, Zhang Z, Tian Q, Wen X, Yu P, Wang D, Cui W, Zhou L, Park E, Baker AJ, Zhang J, Jiang R. A rat model of chronic subdural hematoma: insight into mechanisms of revascularization and inflammation. Brain Res. 2015;1625:84–96. doi: 10.1016/j.brainres.2015.08.017.
    1. Stanisic M, Lyngstadaas SP, Pripp AH, Aasen AO, Lindegaard KF, Ivanovic J, Ilstad E, Konglund A, Sandell T, Ellingsen O, Saehle T. Chemokines as markers of local inflammation and angiogenesis in patients with chronic subdural hematoma: a prospective study. Acta Neurochir (Wien) 2012;154:113–20. doi: 10.1007/s00701-011-1203-2.
    1. Suzuki M, Endo S, Inada K, Kudo A, Kitakami A, Kuroda K, Ogawa A. Inflammatory cytokines locally elevated in chronic subdural haematoma. Acta Neurochir (Wien) 1998;140:51–5. doi: 10.1007/s007010050057.
    1. Tao Z, Lin Y, Hu M, Ding S, Li J, Qiu Y. Mechanism of subdural effusion evolves into chronic subdural hematoma: IL-8 inducing neutrophil oxidative burst. Med Hypotheses. 2016;86:43–6. doi: 10.1016/j.mehy.2015.11.027.
    1. Vaquero J, Zurita M, Cincu R. Vascular endothelial growth-permeability factor in granulation tissue of chronic subdural haematomas. Acta Neurochir (Wien) 2002;144:343–6. doi: 10.1007/s007010200047.
    1. Zarkou S, Aguilar MI, Patel NP, Wellik KE, Wingerchuk DM, Demaerschalk BM. The role of corticosteroids in the management of chronic subdural hematomas: a critically appraised topic. Neurologist. 2009;15:299–302. doi: 10.1097/NRL.0b013e3181b65558.
    1. Berghauser Pont LME, Dammers R, Schouten JW, Lingsma HF, Dirven CMF. Clinical factors associated with outcome in chronic subdural hematoma: a retrospective cohort study of patients on preoperative corticosteroid therapy. Neurosurgery. 2012;70:873–80. doi: 10.1227/NEU.0b013e31823672ad.
    1. Decaux O, Cador B, Dufour T, Jégo P, Cazalets C, Laurat E, Grosbois B. Nonsurgical treatment of chronic subdural hematoma with steroids: two case reports. Rev Med Interne. 2002;23:788–91. doi: 10.1016/S0248-8663(02)00676-8.
    1. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Rodríguez-Salazar A, Galacho-Harriero AM, Fernández-Arconada O. Dexamethasone treatment in chronic subdural haematoma. Neurocirugia (Astur) 2009;20:346–59. doi: 10.1016/S1130-1473(09)70154-X.
    1. Dran G, Berthier F, Fontaine D, Rasenrarijao D, Paquis P. Effectiveness of adjuvant corticosteroid therapy for chronic subdural hematoma: a retrospective study of 198 cases. Neurochirurgie. 2007;53:477–82. doi: 10.1016/j.neuchi.2007.09.146.
    1. Sun TFD, Boet R, Poon WS. Non-surgical primary treatment of chronic subdural haematoma: preliminary results of using dexamethasone. Br J Neurosurg. 2005;19:327–33. doi: 10.1080/02688690500305332.
    1. Thotakura AK, Marabathina NR. Nonsurgical treatment of chronic subdural hematoma with steroids. World Neurosurg. 2015;84:1968–72. doi: 10.1016/j.wneu.2015.08.044.
    1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–33. doi: 10.1097/00005650-199603000-00003.
    1. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86. doi: 10.1093/geront/9.3_Part_1.179.
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98. doi: 10.1016/0022-3956(75)90026-6.
    1. Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke. 1988;19:1497–500. doi: 10.1161/01.STR.19.12.1497.
    1. Weigel R, Schilling L, Schmiedek P. Specific pattern of growth factor distribution in chronic subdural hematoma (CSH): evidence for an angiogenic disease. Acta Neurochir (Wien) 2001;143:811–8. doi: 10.1007/s007010170035.
    1. Friede RL, Schachenmayr W. The origin of subdural neomembranes. I. Fine structural of neomembranes. Am J Pathol. 1978;92:69–84.
    1. Kawakami Y, Chikama M, Tamiya T, Shimamura Y. Coagulation and fibrinolysis in chronic subdural hematoma. Neurosurgery. 1989;25:25–9. doi: 10.1227/00006123-198907000-00005.
    1. Berghauser Pont LME, Dirven CMF, Dippel DWJ, Verweij BH, Dammers R. The role of corticosteroids in the management of chronic subdural hematoma: a systematic review. Eur J Neurol. 2012;19:1397–403. doi: 10.1111/j.1468-1331.2012.03768.x.
    1. Volkmann ER, Rezai S, Tarp S, Woodworth TG, Furst DE. We still don’t know how to taper glucocorticoids in rheumatoid arthritis, and we can do better. J Rheumatol. 2013;40:1646. doi: 10.3899/jrheum.130019.
    1. Richter B, Neises G, Clar C. Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. Endocrinol Metab Clin North Am. 2002;31:751. doi: 10.1016/S0889-8529(02)00008-7.
    1. Brignola C, De Simone G, Belloli C, Iannone P, Belluzzi A, Gionchetti P, Campieri M, Barbara L. Steroid treatment in active Crohn’s disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther. 1994;8:465. doi: 10.1111/j.1365-2036.1994.tb00316.x.
    1. Hings IM, Filipovich AH, Miller WJ, Blazar BL, McGlave PB, Ramsay NK, Kersey JH, Weisdorf DJ. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation. 1993;56:577. doi: 10.1097/00007890-199309000-00016.
    1. Xu C, Chen S, Yuan L, Jing Y. Burr-hole irrigation with closed-system drainage for the treatment of chronic subdural hematoma: a meta-analysis. Neurol Med Chir (Tokyo) 2016;56:62–8. doi: 10.2176/nmc.ra.2015-0013.
    1. Santarius T, Kirkpatrick PJ, Ganesan D, Chia HL, Jalloh I, Smielewski P, Richards HK, Marcus H, Parker RA, Price SJ, Kirollos RW, Pickard JD, Hutchinson PJ. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. Lancet. 2009;374:1067–73. doi: 10.1016/S0140-6736(09)61115-6.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する